Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.72−0.24 (-3.02%)
Close on Nov 19, 2026Market cap $1.27BP/E –Yield –
Novavax operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Novavax's operating income for the twelve months ending Jun 30, 2026 was -$234.12M, down 166.6% year over year. For fiscal 2025 it was $452.80M. The highest annual figure on record is $452.80M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $452.80M | – |
| FY2024 | Dec 31, 2024 | -$248.93M | – |
| FY2023 | Dec 31, 2023 | -$566.51M | – |
| FY2022 | Dec 31, 2022 | -$644.74M | – |
| FY2021 | Dec 31, 2021 | -$1.69B | – |
| FY2020 | Dec 31, 2020 | -$416.72M | – |
| FY2019 | Dec 31, 2019 | -$120.58M | – |
| FY2018 | Dec 31, 2018 | -$173.92M | – |
| FY2017 | Dec 31, 2017 | -$171.71M | – |
| FY2016 | Dec 31, 2016 | -$269.11M | – |
| FY2015 | Dec 31, 2015 | -$157.24M | – |
| FY2014 | Dec 31, 2014 | -$83.69M | – |
| FY2013 | Dec 31, 2013 | -$52.43M | – |
| FY2012 | Dec 31, 2012 | -$29.67M | – |
| FY2011 | Dec 31, 2011 | -$21.58M | – |
| FY2010 | Dec 31, 2010 | -$38.49M | – |
| FY2009 | Dec 31, 2009 | -$37.38M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$54.91M | -154.3% |
| Q1 FY2026 | Mar 31, 2026 | -$15.43M | -103.0% |
| Q4 FY2025 | Dec 31, 2025 | $14.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -$178.02M | – |
| Q2 FY2025 | Jun 30, 2025 | $101.07M | -37.2% |
| Q1 FY2025 | Mar 31, 2025 | $515.51M | – |
| Q4 FY2024 | Dec 31, 2024 | -$131.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -$134.02M | – |
| Q2 FY2024 | Jun 30, 2024 | $161.00M | +190.3% |
| Q1 FY2024 | Mar 31, 2024 | -$144.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$183.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$125.63M | – |
| Q2 FY2023 | Jun 30, 2023 | $55.46M | – |
| Q1 FY2023 | Mar 31, 2023 | -$312.77M | -249.4% |
| Q4 FY2022 | Dec 31, 2022 | -$243.88M | – |
| Q3 FY2022 | Sep 30, 2022 | -$127.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$482.96M | – |
| Q1 FY2022 | Mar 31, 2022 | $209.29M | – |
| Q4 FY2021 | Dec 31, 2021 | -$824.97M | – |
| Q3 FY2021 | Sep 30, 2021 | -$307.14M | – |
| Q2 FY2021 | Jun 30, 2021 | -$345.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$208.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$182.85M | – |
| Q3 FY2020 | Sep 30, 2020 | -$193.94M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.90M | – |
| Q4 FY2019 | Dec 31, 2019 | -$28.71M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.99M | – |
| Q2 FY2019 | Jun 30, 2019 | -$36.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$40.22M | – |
| Q4 FY2018 | Dec 31, 2018 | -$46.51M | – |
| Q3 FY2018 | Sep 30, 2018 | -$41.90M | – |
| Q2 FY2018 | Jun 30, 2018 | -$41.99M | – |
| Q1 FY2018 | Mar 31, 2018 | -$43.51M | – |
| Q4 FY2017 | Dec 31, 2017 | -$47.78M | – |
| Q3 FY2017 | Sep 30, 2017 | -$41.63M | – |
| Q2 FY2017 | Jun 30, 2017 | -$41.47M | – |
| Q1 FY2017 | Mar 31, 2017 | -$40.83M | – |
| Q4 FY2016 | Dec 31, 2016 | -$54.05M | – |
| Q3 FY2016 | Sep 30, 2016 | -$63.31M | – |
See a number that looks wrong?